People · Operator
Named in public records as an officer, director or promoter · active 2022–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Rebalance Health, Inc. | — | Biotechnology | Series A | $21.7M | $58.9M | 2022 |
Randy A. Hetrick at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Randy A. Hetrick on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Scott L. Glenn | 1 | 9 |
| Patrick A. Hopf | 1 | 3 |
| Mark C. McKenna | 1 | 2 |
| Fabian C. Seelbach | 1 | 1 |
| James B. Breitmeyer | 1 | 1 |
| Justin A. Hai | 1 | 1 |
| Fabian C. Sellbach | 1 | 1 |
| Charles L. Kloeris | 1 | 1 |
| Randy L. Hetrick | 1 | 1 |
| James L. Breitmeyer, M.D., Ph.D. | 1 | 1 |
| Patrick L. Hopf | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.